𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

✍ Scribed by N. Barnes; I. Pavord; A. Chuchalin; J. Bell; M. Hunter; T. Lewis; D. Parker; M. Payton; L. Pearce Collins; R. Pettipher; J. Steiner; C. M. Perkins

Book ID
108689017
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
638 KB
Volume
42
Category
Article
ISSN
0954-7894

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

Fontolizumab in moderate to severe Crohn
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
✍ Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Se 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Background: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptom